インタラクティブブレイクアウトディスカッション

ブレイクアウトディスカッションは、承認制の非公式なディスカッションで、特定のトピックについてアイデアや経験を交換し、将来のコラボレーションを築くことができます。各ディスカッションは、ファシリテーターが主導し、ディスカッションの進行とグループの活性化を図ります。この形式を最大限に活用するために、自分の研究事例を共有し、集団で問題解決に取り組むセッションに参加し、活発なアイデアの共有をご準備ください。

すべてのブレイクアウトディスカッションは、対面のみで行われます。

Bi & Multispecific Engineering
Bi and Multispecific T Cell Engagers in an Era of Increased Awareness of Tumor and Patient Heterogeneity
Moderator: Siddhartha Roychoudhury, PhD, Asset Leader, Immuno-Oncology Development, Astellas Pharma

How do we go about selecting the right tumors for the right MOA?
How can we explore novel approaches to MOA-driven patient enrichment?
How can we develop options for rational combinations?

Breakthroughs in Cell Therapy
New Opportunities to Promote Tumor Antigen Presentation through Myeloid Cell Therapies
Moderator: Warren Anderson, PhD, Scientist III, Immunology, Inceptor Bio

Recent technological advances have made concepts like tumor vaccines or transgenic TCRs more promising than ever. Can myeloid cell therapies perform similarly with reduced labor and cost?
What have we learned thus far about the practical limitations of generating myeloid-based cell therapies? What has succeeded?
Considering the successes of CAR Ts or T-cell directed therapies, how should we approach the idea of myeloid based cell therapies? Competitor or teammate?

Bridging Science and Support: Integrative Strategies in Cell Therapy
Moderator: David James, Resident Physician, Ric Scalzo Institute for Botanical Research, Naturopathic Specialists LLC

Exploring how integrative and naturopathic oncology can support patients undergoing advanced immune therapies such as CAR T-cell, bispecific antibodies, NK cell vaccines, and dendritic cell therapy
Clinical applications for monitoring immune therapy response and toxicity using biomarkers and interleukin profiling (e.g., IL-6, IL-8, IL-1β, VEGF, MMP9, TNF-α) from a patient-centered lens
Practical strategies for managing treatment-related adverse events (cytokine release syndrome, neurotoxicity, fatigue) through evidence-informed supportive care
Shared decision-making models to align complex therapies with patient values and quality-of-life goals
Real-world insights into harmonizing conventional protocols with integrative care to improve outcomes and experience

Translating Multispecific Success
What Are We after with Bispecific Targeting of Solid Tumors?
Moderator: Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics

What unmet need is driving bispecific targeting? Efficacy? Width of applicability? Safety? What strategies are needed?
Is there a special place for biparatopic targeting?
Is companion diagnostic a must-have for developing bispecific targeting? Does it need to be quantitative?
Bispecific versus combination: major pros and cons

Autoimmunity
Learnings from I-O for I&I
Moderator: Marc A. Gavin, PhD, Senior Research Fellow & Head, Immunology, InduPro

Depleting pathogenic immune cells: Will TCEs be as potent as CAR T, within tolerated dose windows?
KIR+ CD8 Tregs: Do they respond to current therapies, and does it matter?
Agonizing cytokine receptors: Do feedback mechanisms make it too complicated?

Antibody-Drug Conjugates
Selecting ADC Design Features for a Specific Target and Indication
Moderator: Ian Nessler, PhD, Senior Scientist II, Quantitative, Translational, and ADME Sciences, AbbVie

Target Characterization: Expression and Internalization Profile
Design Considerations for Heme vs. Solid Tumor Indications
Payload Selection (Bystander vs. Non-Bystander Payloads)
Future Directions and Novel ADC Formats

Innate Immunity
Translating in vitro Immuno-Oncology Models to in vivo Impact
Moderator: Craig Thalhauser, PhD, Senior Director, Clinical Pharmacology & Quantitative Sciences, Genmab US Inc

What limits current in vitro models from accurately reflecting the complex tumor microenvironment and in vivo bispecific antibody activity?
Designing in vitro assays that better predict targeted efficacy and potential for off-target effects within the TME
Promising in vitro technologies for predicting in vivo bispecific antibody behavior

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language